LEAP THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
|---|---|---|
| | | LEAP THERAPEUTICS, INC. |
| | | |
| March 15, 2024 | | |
| By: | | /s/ DOUGLAS E. ONSI |
| | | Name: Douglas E. Onsi |
| | | Title: President, Chief Executive Officer and Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| NAME | TITLE | DATE | ||
|---|---|---|---|---|
| | | | | |
| | | Chief Executive Officer, President, Chief | | |
| /s/ DOUGLAS E. ONSI | | Financial Officer and Director (Principal | | March 15, 2024 |
| Douglas E. Onsi | | Executive Officer and Principal Financial Officer) | | |
| | | | | |
| /s/ CHRISTOPHER K. MIRABELLI | | Chairman of the Board of Directors | | March 15, 2024 |
| Christopher K. Mirabelli | | | | |
| | | | | |
| /s/ JAMES CAVANAUGH | | Director | | March 15, 2024 |
| James Cavanaugh | | | | |
| | | | | |
| /s/ THOMAS DIETZ | | Director | | March 15, 2024 |
| Thomas Dietz | | | | |
| | | | | |
| /s/ WILLIAM LI | | Director | | March 15, 2024 |
| William Li | | | | |
| | | | | |
| /s/ JOSEPH LOSCALZO | | Director | | March 15, 2024 |
| Joseph Loscalzo | | | | |
| | | | | |
| /s/ PATRICIA MARTIN | | Director | | March 15, 2024 |
| Patricia Martin | | | | |
| | | | | |
| /s/ NISSIM MASHIACH | | Director | | March 15, 2024 |
| Nissim Mashiach | | | | |
| | | | | |
| /s/ CHRISTIAN RICHARD | | Director | | March 15, 2024 |
| Christian Richard | | | | |
| | | | | |
| /s/ RICHARD L. SCHILSKY | | Director | | March 15, 2024 |
| Richard L Schilsky | | | | |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| | Page |
|---|---|
| | |
| Report of Independent Registered Public Accounting Firm | F-1 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.